Skip to Content
Merck
CN
  • Methylene blue attenuates ischemia--reperfusion injury in lung transplantation.

Methylene blue attenuates ischemia--reperfusion injury in lung transplantation.

The Journal of surgical research (2014-08-26)
Marcus da Matta Abreu, Rogerio Pazetti, Francine Maria de Almeida, Aristides Tadeu Correia, Edwin Roger Parra, Laís Pereira da Silva, Rodolfo de Paula Vieira, Paulo Manuel Pêgo-Fernandes, Fabio Biscegli Jatene
ABSTRACT

Ischemia-reperfusion injury (IRI) is one of the principal obstacles for the lung transplantation (LTx) success. Several strategies have been adopted to minimize the effects of IRI in lungs, including ex vivo conditioning of the grafts and the use of antioxidant drugs, such as methylene blue (MB). We hypothesized that MB could minimize the effects of IRI in a LTx rodent model. Forty rats were divided into four groups (n = 10) according to treatment (saline solution or MB) and graft cold ischemic time (3 or 6 h). All animals underwent unilateral LTx. Recipients received 2 mL of saline or MB intraperitoneally before transplantation. After 2 h of reperfusion, arterial blood and exhaled nitric oxide samples were collected and bronchoalveolar lavage performed. Then animals were euthanized, and histopathology analysis as well as cell counts and cytokine levels measurements in bronchoalveolar lavage fluid were performed. There was a significant decrease in exhaled nitric oxide, neutrophils, interleukin-6, and tumor necrosis factor-α in MB-treated animals. PaO2 and uric acid levels were higher in MB group. MB was able in attenuating IRI in this LTx model.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methylene Blue solution, suitable for microbiology
Sigma-Aldrich
Methylene Blue solution, suitable for microscopy
Sigma-Aldrich
Uric acid, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
Methylene Blue solution, concentrate according to Ehrlich, concentrated, aqueous solution
Sigma-Aldrich
Uric acid, ≥99%, crystalline